logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Gang Lu

This inventor holds 14 USPTO granted patents and 10 published patent applications and 5 EPO patents. Top assignee: Celgene Corporation. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gang Lu. Retrieved from https://idiyas.com/inventor/gang-lu-0f4oej2f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 

% Patents Active = 92.9

 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:

goldMedal14 out of 561 
 
Celgene Corporation
 patents

Years Active: 2019-2026

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 12590953 - METHODS FOR SCREENING CEREBLON MODIFYING COMPOUNDS (2026-03-31),
2. 12510533 - Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (2025-12-30),
3. 12486281 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2025-12-02),
4. 12474342 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2025-11-18),
5. 11733233 - Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases (2023-08-22),
6. 11726080 - Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (2023-08-15),
7. 11590117 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2023-02-28),
8. 11460471 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2022-10-04),
9. 11402372 - Methods for screening cereblon modifying compounds (2022-08-02),
10. 11306101 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2022-04-19),
11. 10969381 - Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (2021-04-06),
12. 10830762 - Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases (2020-11-10),
13. 10648983 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2020-05-12),
14. 10245258 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2019-04-02),

Title: Inventor Gang Lu - Revolutionizing Technology in San Diego

Introduction: Gang Lu is a visionary inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Gang Lu holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a background in engineering and a passion for pushing the boundaries of what is possible, Gang Lu has had a successful career marked by numerous breakthrough inventions that have had a significant impact on various industries.

Collaborations: Throughout his career, Gang Lu has collaborated with leading research institutions, universities, and tech companies to further develop and implement his innovative ideas, fostering a culture of creativity and progress.

Conclusion: Gang Lu's relentless pursuit of innovation and his commitment to pushing the limits of technology make him a true pioneer in the field of inventions, with his work continuing to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…